Summary:
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant) versus placebo in subjects with Acute Migraines
Qualified Participants Must:
• Be 18 or older and have on average 2 migraines per month for the last 3 months
Qualified Participants May Receive:
Qualified participants may receive compensation for time and travel, investigational medication and study related treatment at no cost.